The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after [...]
Epeius Biotechnologies Corporation (www.epeiusbiotech.com) announces the results of the clinical study entitled Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, [...]
ARIAD Pharmaceuticals, Inc. announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the second interim efficacy analysis as specified in the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to [...]
GTx, Inc. announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate. Source: General Cancer News Articles Provided by [...]
Synta Pharmaceuticals Corp. announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer (NSCLC), support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort [...]
Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced data from the Phase III PRIMA study. The data showed that continuing Rituxan (rituximab) for two years in patients who responded to initial treatment with Rituxan plus chemotherapy, doubled the likelihood of them living without [...]
Exelixis, Inc. reported interim data from an ongoing Phase 1b/2 study of XL184 in patients with non-small cell lung cancer (NSCLC). Dr. Heather Wakelee from Stanford University School of Medicine in Stanford, CA will present the data in a poster discussion session on Sunday, June 6 at the 2010 [...]
Celldex Therapeutics, Inc. announced that the first patient has been screened in a randomized Phase 2 study of the Company’s novel, first-in- class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. Source: General Cancer News Articles Provided by Cancer Compass
EntreMed, Inc., announced the addition of Dana Farber/Harvard Cancer Center (DF/HCC) to the Phase 2 multi-center study entitled A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Platinum Resistant Ovarian Cancer. Ursula Matulonis, M.D., Associate Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, will [...]
Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, [...]